कंपनी का अवलोकन
Mersana Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing antibody-drug conjugates (ADC) specifically designed for cancer patients facing significant unmet medical needs. The company focuses on advancing Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate currently in Phase 1 clinical trials, alongside XMT-2056, an Immunosynthe candidate. This organization functions within the Healthcare sector, specifically the Biotechnology industry, where innovation in therapeutic modalities is critical for addressing complex oncological challenges. As of the latest data, the company possesses a market capitalization of $145.36M and generates annual revenue of $33.18M while employing 102 individuals. The relatively modest market cap and revenue figures indicate that the company is in an early-stage development phase, prioritizing clinical validation and pipeline expansion over immediate profitability or large-scale commercialization.
वित्तीय स्वास्थ्य
The financial statements for Mersana Therapeutics, Inc. report a trailing twelve-month revenue of $33.18M, contrasted by a net income of -$70,081,000 and an EBITDA of -$66,290,000. The substantial negative net income relative to the revenue stream reveals a cost structure heavily weighted toward research and development expenses, clinical trial costs, and general administrative overheads typical of pre-commercial biotechnology firms. Free cash flow stands at -$43,801,248, indicating that current operations consume more cash than they generate, which limits immediate financial flexibility and reliance on external capital sources. Margin analysis shows a Gross Margin of -108.0%, an Operating Margin of -67.9%, and a Profit Margin of -211.2%, all of which indicate that the company is currently operating at a loss at every level of the income statement due to high upfront investments in drug discovery and clinical programs. The balance sheet holds $56.39M in cash against $2.29M in debt, resulting in a Debt to Equity ratio of N/A, which suggests a conservative capital structure with minimal leverage despite the negative equity implied by losses. A Current Ratio of 1.39 demonstrates that the company maintains sufficient current assets to cover its short-term liabilities, ensuring adequate liquidity to sustain operations through the current fiscal period. Return on Equity is N/A due to the negative equity position, while Return on Assets stands at -36.3%, reflecting that the asset base is currently generating negative returns on the capital invested by shareholders and creditors.
मूल्यांकन आकलन
Valuation metrics for Mersana Therapeutics, Inc. present a complex picture given its unprofitable status, with a P/E Ratio (TTM) of N/A and a Forward P/E of -2.62. The negative forward P/E implies that the market expects earnings to remain negative in the near term, diverging significantly from a trailing P/E that cannot be calculated due to the lack of positive net income. The Price to Book ratio is -2.44, indicating that the market values the company at a negative multiple of its book value, which is consistent with firms that have accumulated significant losses exceeding their asset base. Alternative valuation measures such as the Price to Sales ratio of 4.38 and an EV/EBITDA of -1.38 suggest that investors are pricing the company based on future pipeline potential rather than current cash flows or earnings. The stock trades between a 52-Week High of $30.39 and a 52-Week Low of $5.21, reflecting extreme volatility in its trading range. With a Beta of 0.43, the stock exhibits lower volatility relative to the broader market, suggesting that price movements are less sensitive to general market fluctuations compared to the average large-cap stock.
Growth & Income
Revenue growth year-over-year is recorded at -12.6%, while Earnings Growth (YoY) is N/A, indicating that the company is currently contracting in terms of top-line revenue and has not yet achieved a positive earnings base to measure growth acceleration. The negative revenue growth implies that the company is likely managing its burn rate or has experienced delays in commercialization or reimbursement processes that impact sales realization. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it does not distribute cash to shareholders and instead reinvests all available resources into research, development, and clinical trial expenditures. This reinvestment strategy is standard for clinical-stage biotechs aiming to bring new therapies to market before generating sustainable cash flows. The overall growth and income profile is characterized by a lack of dividend income and negative growth rates, typical of a firm in the deep development phase where capital preservation and pipeline progression are the primary strategic objectives.